Please select this link, to know about participating in our Nutritional Medicine Studies on Neurogenesis

MSA AND PARKINSONíS DISEASE RESEARCH NEWSLETTER  (Jan 05)

View Video: PD Case Report

Know this day,
and lay it to thy heart,
that the Lord, He is God
in heaven above
and upon the earth beneath;
there is none else.

In all the way
which the Lord your God has command you
ye shall walk,
that ye may live,
and that it may be well with you,
and that you may prolong your days
Deuteronomy 3;39. 5;30.

Home page

Next Newsletter
(March 05)

THE NEUROGENIC PROGRAM IN THE TREATMENT OF NEURO-DEGENERATIVE DISORDERS.

John Grinstein Ph.D..
Food Biochemistry Research UK.
www.br13.com
www.shydrager.com
www.jgrinstein.com

INTRODUCTION

Since we first published, in November 2002, the 6 stages on which our Neurogenic Program is based, we have received hundreds of requests, from all over the world, asking us how the medicinal extracts RG-40 and GCRF can be obtained. (Full text of the 2002 Neurogenic Diet, can be found at www.shydrager.com

The RG-40 and the GCRF are medicinal extracts that are produced from organic vegetable sources, mainly selected fruit and vegetables, that have been around for thousand of years.

That is why, during the 15 years or more that these 100% natural preparations have been used, they have never produced any form of adverse reaction or side effect.

For a purely organic extraction, to reach the high stages of enrichment needed to produce significant medicinal results, the use of very large amounts of plant sources are required. It then becomes too expensive and too hard to produce, to manufacture them on a large scale or for commercial use.

However, when these extracts are used within the framework of the Neurogenic Program, it justifies the effort involved in producing them. The results they produce are much more significant than merely alleviating the symptoms of a human disease.

The RG-40 and GCRF, when used in the context of the Neurogenic Program, are demonstrating that some areas of the human brain, which have been previously damaged or became dormant, can regenerate and restore their previous neuronal activity.

There is then obviously a real incentive to support and sponsor the provision of these medicinal extracts, because their research projects are demonstrating that the ageing process of the human brain, can somehow be modulated.

Almost every theory of ageing today agrees that neuronal chemistry is what governs the main biological ageing clocks.

In Part, of this Newsletter, we will try to define and explain how our Neurogenic Program works. In Part 2,  we will present details of cases in which the neurogenic program has already produced some very important results.

PART 1

In this newsletter we will try to explain why patients, who followed faithfully the recommendation of our neurogenic diet, were able to find that their MSA or their Parkinsonian symptoms had gradually disappeared.

The main differences between the neurogenic diet and all other drugs and medicines to treat Parkinsonís Disease (PD) today, are the following:

1.- With the Neurogenic Diet, patients gradually require the prescribed PD drugs, less times per day, in order to be able to perform their daily activities.

With the PD drugs, patients have to gradually increase the number of times per day they take their drugs, in order to be able perform their daily activities.

2.- With the Neurogenic Diet, patients find out that every month, they can decrease the level of the drugs they have been prescribed.

For example, if they required a dose of one tablet of Sinemet of 200 mg Dopa/50 mg Carbidopa, in order to get a proper 3 hours ON period, when following the Neurogenic Diet, they can get the same 3 hours of ON period, when taking only half of the potency of Sinemet. That is, they require one Sinemet of 100 mg Dopa/25 mg Carbidopa.

3.- It is important to maintain the use of Sinemet at a regular low level, because when Sinemet is used more than 3 times per day, it will rapidly create the a need of increasing it to 5 times a day, then to 7, and then to 12 or more.

When Sinemet is taken more than 3 times per day, the endogenous (self production) of dopa and dopamine in cells and neurons in the brain, starts to become inhibited.

The more times per day a patient takes Sinemet, the more the self synthesis of dopamine is inhibited. The patient becomes more and more dependent on an external source of L-Dopa.

With time, the self synthesis of these transmitters in cells and neurons in the brain, becomes atrophied.

In the same way as an athlete who does not practice, atrophies the ability of his muscles, or a person who had an accident and remains in a wheelchair atrophies his muscles, instead of exercising to reactivate them.

4.- When Sinemet needs to be taken 5 or 10 times a day or more, it alters from being, the most efficient drug to treat Parkinsonís disease, into the originator of a number of intolerable adverse reactions and side effects.

These adverse reactions are usually not noticeable, when a PD patient is using Sinemet no more than 2 or 3 times a day.

5.- Can then we maintain Sinemet at a maximum of 3 times a day during the whole course of the disease?. Unfortunately this is almost impossible, because of the chemistry of dopamine synthesis in the brain.

The more that an external source of L-Dopa is introduced into the system, the less L-Dopa that is produced within the system.

The above, is important to understand, so we will try to explain it in easy terms.

The brainís dopamine chemistry works as follows:

a.- Tyrosine is an amino acid present in almost all foods. In normal subjects, part of the tyrosine taken as food, is converted to L-Dopa. In Parkinsonís Disease this enzymatic process is defective.

 

b.- The enzyme that takes molecules of Tyrosine to convert them to L-Dopa is called Tyrosine Hydroxylase. The only difference between the molecules of Tyrosine and those of L-Dopa, is a hydroxylic group (OH) that this enzyme adds to each molecule of Tyrosine to make L-Dopa.

Fig 1. TH = Tyrosine Hydroxylase; DC = Dopa decarboxylase;
DA = Dopamine

The amount of L-Dopa needed by the brain is self regulated. That is, the more L-Dopa present in the system, the less L-Dopa that will be synthesized from Tyrosine. In this way, every time a patient takes Sinemet and introduces an external source of L-Dopa, he is sending a signal to the enzyme to stop synthesizing L-Dopa.

c.- This process is called enzymatic feedback inhibition. Tyrosine is called the substrate, L-Dopa is called the product and Tyrosine Hydroxylase is the enzymatic machinery that makes L-Dopa from Tyrosine.

d.- When the product of an enzyme, in this case L-Dopa, is higher than required, the excess L-Dopa, surrounding the enzyme, attaches and binds to an active site in the enzyme, to signal the stopping of the making of L-Dopa.

e.- This kind of molecular brake, regulates most of the enzymatic processes of living cells. The regulation of the activity of an enzyme, because of an excess of the end product of that enzyme, is called feedback inhibition.

6.- Why do we believe all of this should be known by an MSA or a Parkinsonís disease patient?

Usually PD and MSA patients adjust their own dosages of medication according to their personal need. Therefore, they should know that, whenever they are taking Sinemet, they need to be very careful not to take more than they really need.

An excess of Sinemet by itself, or in combination with other PD drugs, creates a constant external influx of L-Dopa. This external high input of L-Dopa, confuses the dopaminergic regulatory systems, sending feed-back inhibition signals to enzymes to stop the self synthesis of L-Dopa, as if the body were producing it in excess.

The continuous use of an external source of L-Dopa, like Sinemet or most of the other L-Dopa or Dopamine agonists, continuously sends, signals to cancel the self production of L-Dopa. This situation affects most PD patients today. They are really suffering a drug induced atrophy of the enzymatic synthesis of L-Dopa in brain cells.

7.- Now we can understand why, patients taking large dosages of Sinemet and other PD drugs, need to increase their dosages year after year.

This need to increase the dosage of PD drugs year after year, does not occur because the disease is progressing rapidly, but because of the drug induced atrophy of the dopaminergic neurons.

This is exactly what the neurogenic program is able to correct.

8.- Now that we have explained in easy terms the chemistry of the dopaminergic system, it might be easier for us to explain how a patient can determine, by himself, whether he is having an improvement (regenerative process) or a deterioration (degenerative process).

At night and during sleep, L-Dopa and dopamine are needed much less than in the hours of the day, when a person is awake and performing movements. That is why, during the night, the neurotransmitter dopamine, which has been synthesized in the brain from L-Dopa, is able to fill up and accumulate in neuronal areas named synaptic vesicles. These synaptic vesicles are shown in the figure below.

Fig 2. Various dopamine vesicles are shown inside a nerve terminal. Two of them are shown as releasing dopamine into the synapse for a further interaction with dopamine receptors in a second neuron.

9.- To make this process easier to understand, we will assign a number of units to the amount of dopamine synthesized during the sleeping hours at night.

Letís assume that a patient, at the time of awakening in the morning, has a total of 100 units of dopamine synthesized during the night. These 100 units had been synthesized using all the available neurons producing dopamine in the brain.

As soon as the person starts his early morning activities, letís say at 7 am, the dopamine reserves that were accumulated during the night, will now be used and will become exhausted by about 8 am. At this time, the total amount of dopamine units left will be less than 10. The patient will now find it very difficult to perform any movements. The PD medications will need to be taken at 8 am.

Letís assume now that the patient has started to use Sinemet also during the night. We now know that adding the use of Sinemet at night, will decrease even more the self production of dopamine during the sleeping hours. In this case, the total amount of dopamine units the patient will have available at 7 am, the time of awakening, will be just 10. The need for the first dosage of PD medication will now have to be taken at 7 am., as soon as waking up.

10.- In patients following the Neurogenic Program, the reverse of the above is exactly what occurs.

In patients following the Neurogenic Program, during the hours of sleep at night, there is an increasing number of neurons synthesizing dopamine and also a reactivation of the enzyme tyrosine hydroxylase. As a consequence, much more L-Dopa can now be synthesized. Dopa is then converted to dopamine and the units of dopamine available at the time of awakening, is now over 300.

With 300 units of dopamine, when the patient awakes at 7 am, he is able to function normally without the need of his PD medication, until at least 10 am.

After one year on the Neurogenic Program, patients are able to increase the units of dopamine produced at night to 500 units or more. This is possible, because the number of active dopaminergic neurons has increased and the number of active molecules of the enzyme Tyrosine Hydroxylase has also increased significantly.

Fig 3. Release of Neurotransmitter Dopamine. The red circle shows an enlarged view of the neuronal synapse, the area where dopamine signals sent by one neuron are received by another neuron.

11.- Externally, this neuro-regenerative process can be demonstrated when observing that the patient is able to function normally, without the need of any PD medication until midday.

This can occur mainly because the amount of dopamine produced during the night and also at any time of the day is now much higher. There are now much more active neurons synthesizing L-Dopa than there were a year ago.

With a higher synthesis of L-Dopa, during the day and night, patients will not suffer depletion of dopamine. Externally, this sudden depletion of the neurotransmitter dopamine, is known as freezing episodes and OFF periods.

12.- As a result of following The Neurogenic Program, there is an improved ability of dopaminergic neurons to synthesize L-Dopa, dopamine and neurotrophic factors like GDNF.

That is why, with the Neurogenic Program, the need for PD drugs and all other external sources of L-Dopa, is greatly diminished. The most significant and immediate benefit for the patient is the decrease or suppression of adverse reactions.

By regaining the ability of neurons to synthesize L-Dopa, without the need of external sources, the patient initiates the real healing process.

OFF periods and freezing episodes are short periods in which PD patients are unable to perform almost any movements at all.

Freezing episodes occur only in patients who have been using Sinemet or other sources of L-Dopa for some years.

OFF periods and freezing episodes are external manifestations of what started at the cellular level with the inhibition of the endogenous (self) synthesis of L-Dopa.

Patients suffering with Parkinsonís disease, for periods as long as 10 or 12 years, who never used Sinemet or other forms of L-Dopa, never experienced OFF periods or freezing episodes during their lifetime.

This confirms that OFF periods and freezing episodes are produced only as a consequence of the inhibition of the self synthesis of L-Dopa, that occurs after taking drugs containing L-Dopa.

13.- What then is the Neurogenic Program all about?

The Neurogenic Program provides suggestions, based on scientific knowledge and peer reviewed medical information, to improve health. It provides advice and indications on how to amend errors and resolve problems related to neurodegenerative diseases.

The Neurogenic Program provides a set of guidelines to doctors, health practitioners and caregivers, to improve the health of sufferers from neurodegenerative disorders.

 

Home page

Next Newsletter (March 05)

Please do not hesitate to contact us if you require any further information on the above subject, or if you wish to participate in our studies.

E-mail:
research@rg-40.com

Telephone: (24 hours Monday to Thursday)                          
From the USA:              01144 7930 915 588       
From the UK:               07930 915 588
From other countries     0044 7930 915 588

FAX:
From the USA:              01144 7939 010 379
From the UK:               07939 010 379
From other countries     0044 7939 010 379

Nutritional Medicine Research UK
www.rg-40.com
www.br13.com
www.shaydrager.com
www.jgrinstein.com

Home page

Next Newsletter (March 05 )

[Home] [January 05] [March 05] [May 05] [July  05] [September 05] [December 05] [Untitled15]